Cirrus Therapeutics, an ocular immunology-focused biotech, announced today the close of an $11 million seed financing to advance its pipeline of gene and cell therapies aimed at improving quality of life and extending the ocular healthspan of patients with chronic blinding diseases. The round was led by ClavystBio, with participation from Polaris Partners and SEEDS.
Cirrus Therapeutics has raised an $11 million seed round toward its bet that altering the immune function of the eye using gene therapy can slow or potentially stop aging-related conditions that rob people of their sight.
Uveitis is characterized by inflammation of the uvea and primarily affects adults aged 20 to 50 years. For noninfectious anterior uveitis, corticosteroid eyedrops are first-line treatment. For posterior noninfectious uveitis, disease-modifying antirheumatic drugs are first-line therapy; biologics su …
The Foundation Fighting Blindness and the Retinal Degeneration Fund (RD Fund) hosted their annual Investing in Cures Summit (ICS) on March 21 and 22, 2025 in Tampa to highlight the strong progress in development of treatments and cures for the entire spectrum of retinal degenerative diseases.
The “Aging Well Podcast” is about, well…aging. It’s for people of all ages who are interested in aging successfully. The topics include the Spiritual, Physical, Intellectual, Emotional, and Social dimensions of wellness as they relate to living as well and as long as possible, as well as the financial, legal, and housing questions that everyone has about aging well. Do you have a question you want answered or topic you want discussed on the “Aging Well Podcast”? Send us an email to agingwell.podcast@gmail.com or record your question for us to use in an upcoming episode at following link: Record a message
A Cambridge-based therapeutics company is working on a gene therapy aimed at a key protein in the eye that it says will help older adults against macular degeneration
June 5, 2024 (Cambridge, MA) – Cirrus Therapeutics, the University of Bristol, and London’s Global University Institute of Ophthalmology have discovered a revolutionary treatment for age-related macular degeneration (AMD), the leading cause of vision loss among older adults. Featured on the cover of the journal Science Translational Medicine, this breakthrough research reveals that boosting a specific protein, […]
Working together towards common goals strengthens bonds among community members.
Increasing the levels of a key protein in eye cells may help protect against age-related macular degeneration (AMD), according to new research led by the University of Bristol.
Chronic inflammation is a constitutive component of many age-related diseases, including age-related macular degeneration (AMD). Here, we identified interleukin-1 receptor–associated kinase M (IRAK…